These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 33135822)

  • 1. Codelivery of survivin inhibitor and chemotherapeutics by tumor-derived microparticles to reverse multidrug resistance in osteosarcoma.
    Wei D; Li C; Ye J; Xiang F; Xu Y; Liu J
    Cell Biol Int; 2021 Feb; 45(2):382-393. PubMed ID: 33135822
    [TBL] [Abstract][Full Text] [Related]  

  • 2. YM155 inhibits tumor growth and enhances chemosensitivity to cisplatin in osteosarcoma.
    Gao JZ; Chen FH; Wang L; Wei H; Meng SL
    Eur Rev Med Pharmacol Sci; 2015; 19(11):2062-9. PubMed ID: 26125270
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Small Molecule Survivin Inhibitor YM155 Displays Potent Activity Against Human Osteosarcoma Cells.
    Zhang S; Wang X; Gu Z; Wang L
    Cancer Invest; 2016 Sep; 34(8):401-7. PubMed ID: 27559851
    [TBL] [Abstract][Full Text] [Related]  

  • 4. YM155 enhances the cytotoxic activity of etoposide against canine osteosarcoma cells.
    Ong SM; Saeki K; Kok MK; Nakagawa T; Nishimura R
    J Vet Med Sci; 2019 Aug; 81(8):1182-1190. PubMed ID: 31308291
    [TBL] [Abstract][Full Text] [Related]  

  • 5. YM155 reverses rapamycin resistance in renal cancer by decreasing survivin.
    Koike H; Nitta T; Sekine Y; Arai S; Furuya Y; Nomura M; Matsui H; Shibata Y; Ito K; Oyama T; Suzuki K
    J Cancer Res Clin Oncol; 2014 Oct; 140(10):1705-13. PubMed ID: 24916171
    [TBL] [Abstract][Full Text] [Related]  

  • 6. YM155 Reverses Statin Resistance in Renal Cancer by Reducing Expression of Survivin.
    Nitta T; Koike H; Miyao T; Miyazawa Y; Kato H; Furuya Y; Sekine Y; Suzuki K
    Anticancer Res; 2017 Jan; 37(1):75-80. PubMed ID: 28011476
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Silencing of survivin using YM155 induces apoptosis and chemosensitization in neuroblastomas cells.
    Liang H; Zhang L; Xu R; Ju XL
    Eur Rev Med Pharmacol Sci; 2013 Nov; 17(21):2909-15. PubMed ID: 24254560
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of YM155 on survivin levels and viability in neuroblastoma cells with acquired drug resistance.
    Voges Y; Michaelis M; Rothweiler F; Schaller T; Schneider C; Politt K; Mernberger M; Nist A; Stiewe T; Wass MN; Rödel F; Cinatl J
    Cell Death Dis; 2016 Oct; 7(10):e2410. PubMed ID: 27735941
    [TBL] [Abstract][Full Text] [Related]  

  • 9. YM155, a novel small-molecule survivin suppressant, induces regression of established human hormone-refractory prostate tumor xenografts.
    Nakahara T; Kita A; Yamanaka K; Mori M; Amino N; Takeuchi M; Tominaga F; Hatakeyama S; Kinoyama I; Matsuhisa A; Kudoh M; Sasamata M
    Cancer Res; 2007 Sep; 67(17):8014-21. PubMed ID: 17804712
    [TBL] [Abstract][Full Text] [Related]  

  • 10. YM155 Reverses Cabazitaxel Resistance in Castration-resistant Prostate Cancer by Reducing Survivin Expression.
    Miyao T; Koike H; Sekine Y; Ohtsu A; Oka D; Suzuki K
    Anticancer Res; 2020 Sep; 40(9):5091-5095. PubMed ID: 32878797
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antitumor activity of YM155, a selective small-molecule survivin suppressant, alone and in combination with docetaxel in human malignant melanoma models.
    Yamanaka K; Nakahara T; Yamauchi T; Kita A; Takeuchi M; Kiyonaga F; Kaneko N; Sasamata M
    Clin Cancer Res; 2011 Aug; 17(16):5423-31. PubMed ID: 21737502
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of survivin in the progression of pancreatic ductal adenocarcinoma (PDAC) and a novel survivin-targeted therapeutic for PDAC.
    Brown M; Zhang W; Yan D; Kenath R; Le L; Wang H; Delitto D; Ostrov D; Robertson K; Liu C; Pham K
    PLoS One; 2020; 15(1):e0226917. PubMed ID: 31929540
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Survivin inhibitor YM-155 sensitizes tumor necrosis factor- related apoptosis-inducing ligand-resistant glioma cells to apoptosis through Mcl-1 downregulation and by engaging the mitochondrial death pathway.
    Premkumar DR; Jane EP; Foster KA; Pollack IF
    J Pharmacol Exp Ther; 2013 Aug; 346(2):201-10. PubMed ID: 23740602
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antitumor activity of YM155, a selective survivin suppressant, in combination with cisplatin in hepatoblastoma.
    Yu Y; Zhao X; Zhang Y; Kang Y; Wang J; Liu Y
    Oncol Rep; 2015 Jul; 34(1):407-14. PubMed ID: 25955434
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dual induction of apoptotic and autophagic cell death by targeting survivin in head neck squamous cell carcinoma.
    Zhang L; Zhang W; Wang YF; Liu B; Zhang WF; Zhao YF; Kulkarni AB; Sun ZJ
    Cell Death Dis; 2015 May; 6(5):e1771. PubMed ID: 26018732
    [TBL] [Abstract][Full Text] [Related]  

  • 16. YM155 sensitizes non-small cell lung cancer cells to EGFR-tyrosine kinase inhibitors through the mechanism of autophagy induction.
    Dai CH; Shu Y; Chen P; Wu JN; Zhu LH; Yuan RX; Long WG; Zhu YM; Li J
    Biochim Biophys Acta Mol Basis Dis; 2018 Dec; 1864(12):3786-3798. PubMed ID: 30315932
    [TBL] [Abstract][Full Text] [Related]  

  • 17. YM155 exerts a growth inhibitory effect on human osteosarcoma in vitro and in vivo.
    Zhang Z; Ma L; Wang J
    Oncol Rep; 2015 Aug; 34(2):1074-80. PubMed ID: 26081496
    [TBL] [Abstract][Full Text] [Related]  

  • 18. YM155, a small molecule inhibitor of survivin expression, sensitizes cancer cells to hypericin-mediated photodynamic therapy.
    Gyurászová K; Mikeš J; Halaburková A; Jendželovský R; Fedoročko P
    Photochem Photobiol Sci; 2016 Jun; 15(6):812-21. PubMed ID: 27241169
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The over-expression of survivin enhances the chemotherapeutic efficacy of YM155 in human hepatocellular carcinoma.
    Xia H; Chen J; Shi M; Deivasigamani A; Ooi LL; Hui KM
    Oncotarget; 2015 Mar; 6(8):5990-6000. PubMed ID: 25714025
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Action of YM155 on clear cell renal cell carcinoma does not depend on survivin expression levels.
    Sim MY; Huynh H; Go ML; Yuen JSP
    PLoS One; 2017; 12(6):e0178168. PubMed ID: 28582447
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.